A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and pharmacoeconomics of oral capecitabine in
patients with metastatic colorectal cancer. The anticipated time on study treatment is 3-12
months, and the target sample size is 28 individuals.